• Supplied in a Pharmacy Bulk Package (PBP). Dispense single doses to multiple patients in a pharmacy admixture program; use within 4 hours of puncture.
  • Must be diluted prior to use.
  • Administer as a slow intravenous infusion.
  • See Full Prescribing Information for important administration instructions.
  • Maximum recommended duration is one week.
Population Recommended Doses
Pediatric Patients age 5 months to less than 12 months 50 mg once daily
Pediatric Patients age 1 year to less than 11 years 100 mg once daily
Adults and Pediatric Patients age 11 years and older 200 mg once daily
Specific Populations
Pregnant women, lactating women, patients with glucose-6-phosphate dehydrogenase deficiency Should not exceed the U.S. Recommended Dietary Allowance (RDA)

DOSAGE AND ADMINISTRATION


Important Preparation and Administration Instructions
  • ASCOR® vials contain 25,000 mg of ascorbic acid and the largest recommended single dose is 200 mg. Do not give the entire contents of the vial to a single patient.
  • Do not administer ASCOR® as an undiluted intravenous injection.
  • Minimize exposure to light because ASCOR® is light sensitive.
  • ASCOR® is supplied as a Pharmacy Bulk Package (PBP) which is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion:
    • Use only in a suitable ISO Class 5 work area such as a laminar flow hood (or an equivalent clean air compounding area).
    • Penetrate each PBP vial closure only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. Given that pressure may develop within the vial during storage, exercise caution when withdrawing contents from the vial.
    • Once the closure system has been penetrated, complete all dispensing from the PBP vial within 4 hours. Each dose must be used immediately. Discard unused portion.
    • Prior to administration, ASCOR® must be diluted in a suitable infusion solution and the final solution for infusion must be isotonic (undiluted the osmolarity of ASCOR® is approximately 5,900 mOsmol/L). Prior to preparing the admixture for infusion, calculate the osmolarity of the intended admixture for infusion. Add one daily dose of ASCOR® directly to an appropriate volume of a suitable infusion solution (e.g. 5% Dextrose Injection, Sterile Water for Injection) and add appropriate solutes, as necessary, to make the final solution isotonic. Sterile Water for Injection is highly hypotonic; adjust solute content, as necessary, to make the final infusion solution isotonic prior to injection. Do not mix ASCOR® with solutions containing elemental compounds that can be reduced (e.g., copper). The concentration of ascorbic acid in the final, admixture solution for infusion is to be in the range of 1 to 25 mg of ascorbic acid per mL. For example, for the largest recommended dose: Add 200 mg of ascorbic acid (equivalent to 0.4 mL of ASCOR®) to 7.5 mL of Sterile Water for Injection to produce an infusion solution having an approximate osmolarity of 290 mOsmol/L. In this specific example, addition of solute is NOT necessary because the solution is isotonic.
    • Prepare the recommended dose based on the patient population.
    • Visually inspect for particulate matter and discoloration prior to administration (the diluted ASCOR® solution should appear colorless to pale yellow).
    • Immediately administer the admixture for infusion as a slow intravenous infusion.

Recommended Dosage
  • Table 1 provides recommended doses of ASCOR® based on patient population and infusion rates of diluted ASCOR® solution.

    Table 1: Recommended Dose of ASCOR® and Infusion Rate of Diluted ASCOR® Solution
    Patient Population ASCOR® Once Daily Dose (mg) Infusion Rate of Diluted ASCOR® Solution (mg/minute)
    Pediatric Patients age 5 months to less than 12 months 50 1.3
    Pediatric Patients age 1 year to less than 11 years 100 3.3
    Adults and Pediatric Patients age 11 years and older 200 33

    The recommended maximum duration of daily treatment with ASCOR® is seven days. If no improvement in scorbutic symptoms is observed after one week of treatment, retreat until resolution of scorbutic symptoms is observed.

    Repeat dosing is not recommended in pediatric patients less than 11 years of age.


Dose Reduction in Specific Populations
  • Women who are pregnant or lactating and patients with glucose-6-dehydrogenase deficiency should not exceed the U.S. Recommended Dietary Allowance (RDA) or daily Adequate Intake (AI) level for ascorbic acid for their age group and condition.

Indication & Important Safety Information


ASCOR® is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated.

Limitations of Use:
ASCOR® is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

Important Safety Information


Contraindications: None.

Administration site reactions include pain and swelling.

ASCOR® should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR® may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache.

Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid. ASCOR® is not indicated for prolonged administration. The maximum recommended duration is one week.

In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred.

Ascorbic acid may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing, nitrite and bilirubin levels, and leucocyte count testing. If possible, laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion of ASCOR®.

Please see accompanying Full Prescribing Information for ASCOR®.

I AM
A HEALTH CARE PROFESSIONAL
I AM NOT
A HEALTH CARE PROFESSIONAL

The information contained in this section of the site is intended for U.S. healthcare professionals only.